IVF Second Cycle Success Rate: What Changes and Why

You have done cycle one. You lived through the injections, the monitoring visits, the trigger, the retrieval, the wait. You know what hCG injections feel like in the wrong spot. You know what bloating means at day 10. You are between cycles now, with the lessons-learned visit either on the calendar or just behind you, and you want to understand what your IVF second cycle success rate actually depends on and which knobs your RE will turn.

Cycle two is the most informative cycle in IVF. We have data now (your data, not the average patient's), and we use it. The discipline that makes cycle two truly informative rather than another expensive guess is changing one variable at a time. This post walks through the data cycle one produced, the lever that addresses each finding, and the add-ons to treat skeptically.

What cycle one actually taught us

A first IVF cycle is a structured experiment your body ran on stims. The output is six categories of data, all of which your clinic has and most of which you can ask for in writing.

• Response to stimulation: total follicle count by day 5, day 8, day 10; peak estradiol; days of stim; final follicle size distribution at trigger.
• Retrieval yield: total oocytes collected, mature MII count, immature (GV and MI) count.
• Fertilization: conventional or ICSI, fertilization rate (2PN per MII), abnormal fertilization (1PN, 3PN).
• Embryo development: day 3 cell counts, blastulation rate, day 5 versus day 6 versus day 7 blast distribution, grades.
• PGT-A results if tested: euploid, mosaic, aneuploid, no-result.
• Transfer outcome: lining thickness and pattern on transfer day, progesterone level, implantation result.

Before cycle two, ask for these in a single summary if you do not already have them. Most clinics will email a discharge summary; some will not unless asked. This is your data. You are allowed to have it.

The change-one-thing principle

If cycle two changes five things and it works, you have no idea which change helped. If cycle two changes five things and it fails, you have no idea what to change for cycle three. Both endings leave you guessing.

So we identify the limiting factor from cycle one and change the lever that addresses it. Yield problem? Stim dose or protocol. Fertilization problem? ICSI or sperm work. Blastulation problem? Egg-quality interventions, harder and slower. Ploidy problem? Mostly age, with limited interventions and more retrievals. Transfer problem? Endometrial work, not stim work.

The lever follows the limiting factor. Not every cycle has an obvious limiting factor, in which case the change might be a refinement (slightly higher FSH, different trigger) rather than a wholesale protocol switch. That is also legitimate.

Common protocol changes by problem

If cycle one was a low-yield cycle

A low-yield cycle is typically defined by Bologna or POSEIDON criteria: fewer than four oocytes despite an adequate stim, or a known poor responder profile. The levers:

• Higher starting FSH dose, sometimes capped around 300-450 IU/day.
• Switch from antagonist to microdose flare or estradiol priming protocols.
• Add LH activity (Menopur, low-dose hCG drip) if cycle one used pure recombinant FSH.
• Consider DHEA or CoQ10 priming for 8-12 weeks pre-cycle, where evidence is mixed but the intervention is reasonable in diminished ovarian reserve and low-cost.
• Banking approach: do two or three retrievals before transferring, accumulating a larger embryo cohort.

ESHRE's 2020 ovarian stimulation guideline covers individualization in detail and is the most current evidence summary.⁶

If cycle one was an over-response or near-OHSS

The lever set runs the other direction:

• Lower starting FSH (often 100-150 IU/day for PCOS profiles).
• Switch from agonist to antagonist if the long agonist was used.
• GnRH agonist trigger or dual trigger to reduce OHSS risk dramatically.
• Freeze-all rather than fresh transfer, both for safety and for FET endometrial-timing benefits.
• Cabergoline post-trigger to reduce VEGF-mediated capillary leak.
• Metformin priming in PCOS profiles, particularly with insulin resistance.

If cycle one had poor fertilization

If conventional insemination was used and fertilization was under 50 percent, the standard change is ICSI in cycle two. This is one of the most evidence-based protocol changes in IVF.

If ICSI was already used and fertilization was poor, the next layer is sperm DNA fragmentation testing, embryologist review of sperm morphology and motility, and discussion of culture media. Some clinics offer testicular sperm extraction (TESE) in severe DNA fragmentation cases, though indications remain case-by-case.

If embryos fertilized but did not reach blastocyst

Poor blastulation despite normal fertilization is one of the harder findings to address, because the underlying mechanism is usually egg quality, which is largely age-determined. The reasonable interventions:

• CoQ10, DHEA, melatonin supplementation for three months pre-cycle. Evidence is mixed but the intervention is low-risk.
• Different culture media or extended day-7 culture at some labs.
• More retrievals to bank a larger cohort. Sometimes a 20-percent blastulation rate just means you need three retrievals to get four blasts.

Be cautious of any single intervention sold as a fix for egg quality. The honest framing is that egg quality is hard to move quickly.

If transfer failed despite a good embryo

The failed-transfer pillar covers the full workup; the short version is that this is an endometrial and technique question, not a stim question. The five-bucket workup in our pillar post applies. Hysteroscopy or SIS, chronic endometritis screen, lining thickness review, progesterone level the day before transfer, trial of natural FET if the first was programmed.

If no euploid embryos came from cycle one

Aneuploidy rates rise steeply with age. At 35 about 50 percent of embryos are euploid; at 40 the number is closer to 30 percent; at 42 it is around 15-20 percent. With small cohorts, getting zero euploid is statistically common at older ages.

The lever set is narrow:

• More retrievals to bank a larger cohort, giving you more shots at the euploid lottery.
• DHEA/CoQ10/melatonin for three months pre-cycle, with the same caveat as above.
• Discussion of donor egg may emerge if cohort-level ploidy is the constraint.

Add-ons: what has evidence and what does not

Cycle two is when the add-on industry starts pitching hardest. Be specific in your questions.

• PGT-A in cycle two after an untested failed cycle one: reasonable, especially over 35, with the caveat that small cohorts can be left with nothing to transfer after testing.
• ICSI after conventional fertilization failed: evidence-based.
• Endometrial scratch: the Lensen et al. NEJM 2019 multicenter RCT showed no benefit. It is reasonable to decline.²
• PRP intrauterine: emerging, not standard, mostly small studies.
• Immune therapy (intralipid, IVIG, prednisolone): ASRM's 2018 guideline advises against routine use in unselected IVF.⁴
• ERA (endometrial receptivity array): Simon et al. 2020 RCT did not support routine use; the test was originally promising in observational data but did not hold up under randomization.³
• Growth hormone adjuvant: mixed evidence in poor responders; reasonable to discuss but not standard.

For any add-on you are offered, ask three questions: what is the live-birth evidence, what is the cost, and what is the actual mechanism it is treating. "It can't hurt" is not a clinical answer.

IVF second cycle success rate: the cumulative math

The most useful number for planning cycle two is cumulative live birth across all transfers from cycle one and cycle two combined. The Smith et al. JAMA 2015 dataset of 156,000 women is the cleanest cumulative-rate publication and remains the citation REs use.¹ Adjusted for current SART data:

• Under 35: cumulative live birth approximately 70-80 percent by end of cycle two across all transfers.
• 35-37: approximately 60-70 percent.
• 38-40: approximately 40-50 percent.
• 41-42: approximately 20-25 percent.

These are pooled estimates. Your clinic and your specific diagnosis will move you up or down. Ask your RE for their clinic-specific number for your age band and AMH range. If they cannot tell you, that is itself useful information.

When to start cycle two

Most clinics ask for at least one full menstrual cycle of recovery after retrieval before restarting stims, and one to two cycles after a failed transfer before another transfer. The biology is that your ovaries need time to return to a quiet baseline, and your endometrium and HPA axis need time to reset after weeks of supraphysiological hormone exposure.

Back-to-back retrievals are possible in banking protocols and used in some poor-responder strategies, with no menstrual cycle in between. The outcome data is mixed. If your clinic proposes this, ask why.

A longer mental health break is reasonable and not a wasted cycle. Many couples take two to four months between cycles for non-medical reasons (work, finances, holidays, grief). The medicine does not get worse during that pause.

When a clinic switch is worth considering before cycle two

After one cycle, a clinic switch is usually not the answer. After two cycles with the same problem and no protocol change, it may be. The signals worth taking seriously:

• Two cycles with no responsive protocol change despite a clear limiting factor.
• Live birth rates clearly below national average for your age and diagnosis on SART CORS data.
• A communication pattern where you cannot get clinical questions answered in writing.
• Insurance changes that force a switch.
• Add-on heavy clinic culture without the underlying evidence work.

A second opinion is reasonable at any point. Most REs do not take it personally.

What to ask before cycle two starts

These questions sharpen the IVF second cycle success rate conversation. Bring them on paper:

1. Based on cycle one, what is the limiting factor we are addressing?
2. What single variable are we changing in cycle two, and why this one?
3. Are any add-ons being added? What is the live-birth evidence for each, and what is the cost?
4. What is my expected cumulative live birth across cycle two transfers?
5. What is the cancellation threshold this time, by follicle count and estradiol?
6. What is the freeze-all rule for this cycle?

What's next

• If cycle two ends with a positive transfer: /two-week-wait/luteal-phase-explained
• If cycle two ends with another failed transfer: /ivf/failed-ivf-transfer-next-steps
• If this is heading toward a third or fourth failed transfer: /ivf/recurrent-implantation-failure
• If cycle two gets cancelled: /ivf/cancelled-ivf-cycle
• If the stopping conversation is starting: /ivf/when-doctors-recommend-stopping-ivf

Sources

1. Smith ADAC, Tilling K, Nelson SM, Lawlor DA. Live-birth rate associated with repeat in vitro fertilization treatment cycles. JAMA 2015;314(24):2654-2662. https://doi.org/10.1001/jama.2015.17296
2. Lensen S, Osavlyuk D, Armstrong S, et al. A randomized trial of endometrial scratching before in vitro fertilization. New England Journal of Medicine 2019;380(4):325-334. https://doi.org/10.1056/NEJMoa1808737
3. Simón C, Gómez C, Cabanillas S, et al. A 5-year multicentre randomized controlled trial comparing personalized, frozen and fresh blastocyst transfer in IVF. Reproductive BioMedicine Online 2020;41(3):402-415. https://doi.org/10.1016/j.rbmo.2020.06.002
4. Practice Committee of the American Society for Reproductive Medicine. The role of immunotherapy in in vitro fertilization: a guideline. Fertility and Sterility 2018;110(3):387-400. https://doi.org/10.1016/j.fertnstert.2018.05.009
5. Polyzos NP, Devroey P. A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel? Fertility and Sterility 2011;96(5):1058-1061.e7. https://doi.org/10.1016/j.fertnstert.2011.09.048
6. ESHRE Guideline Group on Ovarian Stimulation, Bosch E, Broer S, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI. Human Reproduction Open 2020;2020(2):hoaa009. https://doi.org/10.1093/hropen/hoaa009